APTEEUS is a clinical stage biotech company addressing monogenetic disorders. Focusing on the molecular causes of diseases, APTEEUS dedicates its strong experience to the discovery and the development of Disease Modifying Therapies.
APTEEUS most advanced drug-candidate is targetting the common underlying cause of a 6th of patients with a monogenic disease. It is the first therapy that target the mechanism responsible for the decay of mRNA transcripts containing a premature termination codon. APTEEUS harnesses its unique mode of action to address several monogenetic recessive conditions, the first ones being genodermatoses. Phase 1/2 clinical trials are planned for 2019.
APTEEUS implemented a unique technology using patient cells to rapidly expand the use of its drug candidate. APTEEUS is also collaborating with patient associations and Pharmas into Drug Discovery projects for molecule screening on patient primary cells and drug repurposing.
28 February 2019
We are not patients, we are not families, we are not doctors…but we live with rare diseases, we think rare diseases…we are researchers, we are APTEEUS!Read More
19 February 2019
APTEEUS has been awarded at the France Tech Transfer Invest 2019. France Tech Transfer Invest 2019 took place on 13-14 February 2019 in Paris, organised by Tech Tour and hosted by Bpifrance, France’s National Development…Read More
21 December 2018
Apteeus has started a tailor-made research program for the association Les Petits Mec P2. Less than 18 months after the first exchanges with the association and opinion leaders in the field, several thousand molecules for…Read More
11 December 2018Read More
16 April 2018
Rare Disease 360°, Collaborative Strategies to leave no-one behind Proud to present the high potential of APTEEUS Protein Re-expression Therapy, Isabelle will attend the European Conference on Rare Diseases and Orphan Products in Vienne. SHe…Read More